DaVita Inc. (DVA) is a publicly traded Healthcare sector company. As of November 10, 2026, DVA trades at $178.36 with a market cap of $12.04B and a P/E ratio of 14.63. DVA moved -3.36% today. Year to date, DVA is +61.95%; over the trailing twelve months it is +49.93%. Its 52-week range spans $101.00 to $247.49. Analyst consensus is neutral with an average price target of $225.20. Rallies surfaces DVA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Washington state accuses DaVita, Fresenius of suppressing competition: Washington state filed an antitrust lawsuit accusing DaVita and Fresenius Medical Care of using noncompete agreements for kidney specialists, limiting competition among dialysis providers. The state seeks to void the agreements and civil fines of up to $7,500 per violation.
| Metric | Value |
|---|---|
| Price | $178.36 |
| Market Cap | $12.04B |
| P/E Ratio | 14.63 |
| EPS | $12.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $247.49 |
| 52-Week Low | $101.00 |
| Volume | 541.56K |
| Avg Volume | 0 |
| Revenue (TTM) | $14.01B |
| Net Income | $1.19B |
| Gross Margin | 0.00% |
5 analysts cover DVA: 0 strong buy, 2 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $225.20.